BRIEF-Eli Lilly Says FDA Expands Label For Zepbound To Include Four-Dose Single-Patient Use KwikPen
Eli Lilly and Company -1.89% Pre
Eli Lilly and Company LLY | 905.03 909.99 | -1.89% +0.55% Pre |
Feb 23 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY: FDA APPROVED LABEL EXPANSION FOR ZEPBOUND (TIRZEPATIDE) TO INCLUDE FOUR-DOSE SINGLE-PATIENT USE KWIKPEN
ELI LILLY: ZEPBOUND PATIENTS CAN NOW ACCESS ALL DOSES IN EITHER MULTI-DOSE KWIKPEN OR SINGLE-DOSE VIAL STARTING AT $299 PER MONTH FOR 2.5 MG DOSE
ELI LILLY: ZEPBOUND KWIKPEN IS AVAILABLE IN 2.5 MG, 5 MG, 7.5 MG, 10 MG, 12.5 MG, OR 15 MG DOSES
